BAIE D’URFE, QUEBEC, December 19, 2023, Wendy Hauck has been included in Marquis Who’s Who. As in all Marquis Who’s Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

An accomplished expert in medical affairs, drug development, and preclinical and translational cancer research, Dr. Hauck excels as the global medical director of global medical affairs and oncology for Eisai Oncology Medical, where she also works as the RCC/GU & Melanoma lead. Through her work with Eisai, she liaises with regional medical directors and county medical directors worldwide to exchange information, share best practices, and keep each other abreast regarding the drug development process. Likewise, Dr. Hauck gathers information through real-world evidence, examining investigator-initiate and sponsored trials.

Before obtaining her current role with Eisai Oncology, Dr. Hauck was the global associate medical director and breast cancer lead. During the early stages of her career, she gained valuable expertise in medical affairs, global drug development, immunology, and oncology through such companies as Bristol-Myers Squibb, Celgene Canada, Amgen Canada, Bellus Health, Novartis Canada, the Lady Davis Research Institute of Jewish General Hospital, and Montreal General Hospital’s Research Institute.

An expert in her field, Dr. Hauck received a PhD in biochemistry from McGill University in 1993. Subsequently, she expanded her professional knowledge, earning a basics of marketing certificate from the McGill Executive Institute, an orphan drugs clinical trials certificate from Symmetric Training, and a Six Sigma White Belt through LinkedIn. In 2023, she also studied artificial intelligence in pharmaceuticals and biotechnology at the MIT Sloan School of Management. Driven to remain abreast of ongoing industry changes, Dr. Hauck aligns herself with the American Society of Clinical Oncology, the European Society of Medical Oncology, the American Association for Cancer Research, the Society for Gynecologic Oncology, and the International Association for the Study of Lung Cancer.

Due to her considerable knowledge, Dr. Hauck obtained patents for formulations and methods for treating amyloidosis and another for treating renal disorders, diabetic nephropathy, and dyslipidemias. In light of her professional achievements, she has been honored many times, earning several in-company awards. Similarly, she won numerous scholarship grants through Canderel, FRQS, and the Canadian Federation of University Women.

While her career has been filled with highlights, Dr. Hauck takes the most pride in her work at Bellus Health. While working on a drug to address Alzheimer’s disease, she proved that inhibiting amyloid had a positive impact on treating Alzheimer’s.

Though hard work and dedication have brought her far in her career, she credits her success to having a wonderful mentor who guided her throughout her career. Looking ahead, Dr. Hauck intends to leverage her expertise as a consultant and professor.